33rd Bethesda Conference: Preventive cardiology: how can we do better?

*J. Am. Coll. Cardiol.* 2002;40;583

**This information is current as of June 21, 2012**

The online version of this article, along with updated information and services, is located on the World Wide Web at:

[http://content.onlinejacc.org](http://content.onlinejacc.org)
# Table of Contents

- **Introduction** ................................................................. 584

- **Summary Recommendations** ........................................... 585
  - Research ........................................................................... 585
  - Funding ............................................................................. 586
  - Policy ............................................................................... 586
  - Clinical–Educational ......................................................... 587

- **Task Force #1–Magnitude of the Prevention Problem:**
  - Opportunities and Challenges ......................................... 588
    - Epidemiology of CVD ..................................................... 588
    - Cardiovascular Risk Factors: Distribution and Impact of Treatment ......................................................... 590
    - CVD Prevention ............................................................. 592
    - Barriers to Achieving Risk-Factor Reduction ................... 594
    - Approaches to Barriers in CVD Prevention ...................... 597
    - Summary ........................................................................... 598
    - References ....................................................................... 600

- **Task Force #2–The Cost of Prevention: Can We Afford It?**
  - Cost-Effectiveness Analysis of Preventive Strategies:
    - Brief Overview ................................................................ 603
    - Issues in Cost-Effectiveness Analyses .............................. 609
    - Cost Effectiveness Versus Public Policy ............................ 611
    - Cost Effectiveness Versus Total System Costs .................. 612
    - Conclusions ..................................................................... 613
    - References ....................................................................... 613

- **Task Force #3–Getting Results: Who, Where, and How?** .... 615
  - Programs of Governmental and Non-Governmental Organizations ................................................................. 615

- **Task Force #4–Adherence Issues and Behavior Changes:**
  - Achieving a Long-Term Solution ....................................... 630
    - Introduction: The Challenge of Adherence ....................... 630
    - Adherence: A Problem That Must be Addressed on Multiple Levels ................................................................. 631
    - Counseling and Theoretical Models ................................. 633
    - General Strategies for Increasing Adherence .................... 635
    - Risk-Factor-Specific Strategies and Resources for Increasing Adherence ................................................................. 636
    - Summary and Future Directions ....................................... 638
    - References ....................................................................... 638

- **Task Force #5–The Role of Cardiovascular Specialists as Leaders in Prevention: From Training to Champion** .... 641
  - How Much Training in Prevention? .................................... 641
  - What Type of Practitioner Training is Needed? .................... 643
  - How Should Preventive Services be Integrated Into Daily CV Specialty Practice? ................................................................. 644
  - Can CV Specialists be Champions of Prevention? ............... 646
  - What is the Role of Academic Preventive CV Specialists? .... 647
  - References ....................................................................... 648

- **Appendix: Resource Guide** .............................................. 650
33rd Bethesda Conference: Preventive cardiology: how can we do better?

*J. Am. Coll. Cardiol.* 2002;40;583

This information is current as of June 21, 2012

<table>
<thead>
<tr>
<th>Rights &amp; Permissions</th>
<th>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://content.onlinejacc.org/misc/permissions.dtl">http://content.onlinejacc.org/misc/permissions.dtl</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://content.onlinejacc.org/misc/reprints.dtl">http://content.onlinejacc.org/misc/reprints.dtl</a></td>
</tr>
</tbody>
</table>